Silensed anti-CD28 antibodies and use thereof
Details for Australian Patent Application No. 2002226086 (hide)
International Classifications
Event Publications
25 August 2005 Application Accepted
Published as AU-B-2002226086
27 October 2005 Application for Amendment
The nature of the amendment is as shown in the statement(s) filed 04 Oct 2005. Address for service in Australia - Davies Collison Cave Level 15 1 Nicholson Street MELBOURNE VIC 3000
22 December 2005 Standard Patent Sealed
2 February 2006 Change of Name(s) of Applicant(s), Section 104
Fujisawa Pharmaceutical Co., Ltd. The name of the applicant has been changed to Astellas Pharma, Inc.
9 March 2006 Amendment Made
The nature of the amendment is as shown in the statement(s) filed 04 Oct 2005
16 August 2007 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser